Healthcare Reforms Hang in Balance as Funding Deadline Looms

WASHINGTON, D.C. – January 21, 2026 – With a critical government funding deadline just days away, a major industry group is amplifying its call for Congress to pass a spending package that includes significant healthcare reforms aimed at lowering costs and increasing transparency for millions of Americans. The National Association of Benefits and Insurance Professionals (NABIP) has thrown its weight behind several key provisions in the Fiscal Year 2026 Health and Human Services (HHS) funding bill, urging lawmakers to act before current funding expires on January 30.

The proposed measures target some of the most persistent and frustrating aspects of the U.S. healthcare system, including opaque prescription drug pricing, surprise hospital 'facility fees', and inaccurate insurance provider directories. NABIP, which represents over 100,000 insurance agents and benefits professionals, argues these reforms are essential for protecting consumers and employers from runaway costs.

"These reforms move healthcare in the right direction with more transparency, fairer costs, and better protections for consumers," said Jessica Brooks-Woods, CEO of NABIP, in a statement. "They also underscore the vital role agents and brokers play in helping individuals, seniors, and employers make confident coverage decisions."

A High-Stakes Legislative Showdown

The healthcare provisions are embedded within a massive government funding package that is the subject of intense, last-minute negotiations on Capitol Hill. The text of the final appropriations bills, including the one for Labor-Health and Human Services (LHHS), was released on January 20, setting off a race to pass the legislation and avert a government shutdown. The LHHS bill allocates $116.8 billion for HHS, a modest increase over the previous year, but its true impact lies in the policy riders attached to it.

This legislative vehicle has become a battleground for competing interests, with the NABIP-backed reforms representing a significant push to rein in costs. The debate is not merely about budgetary numbers but about fundamentally altering the financial dynamics between patients, providers, insurers, and pharmaceutical middlemen.

Unpacking the Proposed Reforms

NABIP's support centers on four specific areas designed to address major cost drivers and consumer pain points.

First is a push for greater Pharmacy Benefit Manager (PBM) transparency. The proposal would mandate that PBMs—the intermediaries that negotiate drug prices for health plans—pass 100% of the rebates they receive from drug manufacturers back to the health plans. Proponents argue this would shed light on the true cost of prescription drugs and could lead to lower premiums and out-of-pocket costs for consumers and employers.

Second, the package aims to strengthen hospital site neutrality. This provision targets the widespread practice of hospitals charging higher 'facility fees' for services delivered in outpatient clinics that they own, compared to the same service performed in an independent doctor's office. By enforcing more uniform Medicare payments regardless of the site of care, the reform seeks to eliminate this pricing disparity, which can drive up costs for both the Medicare program and patients with private insurance.

Third, the legislation includes measures to improve the accuracy of Medicare Advantage provider networks. Beneficiaries, particularly seniors, often rely on provider directories to choose a plan, only to find the listed doctors are not accepting new patients or are no longer in the network. This can lead to surprise out-of-network bills. The reforms would hold insurers more accountable for maintaining accurate directories, protecting seniors from unexpected costs and enabling benefits professionals to provide more reliable guidance.

Finally, the bill continues funding for the implementation and oversight of the No Surprises Act (NSA). Enacted in 2020, the NSA protects patients from crippling surprise medical bills from out-of-network providers during emergencies or for certain scheduled procedures. Continued enforcement is seen as crucial to solidifying these consumer protections, with a particular focus in 2026 on refining the dispute resolution process and auditing payment calculations.

Industry Lines Are Drawn

While consumer and employer groups largely champion these reforms, they face stiff opposition from powerful industry sectors that benefit from the status quo. The Pharmaceutical Care Management Association (PCMA), which represents PBMs, has argued that forcing a 100% rebate pass-through would limit their ability to negotiate lower drug prices and could restrict the flexibility of employers to design their own health benefits.

Hospital associations, including the American Hospital Association (AHA), are staunchly opposed to expanded site-neutral payment policies. They contend that hospital-based outpatient departments have higher overhead and regulatory costs and that cutting their payments could force them to reduce services and staff, potentially harming access to care in some communities.

This clash sets up a classic Washington showdown: insurers, employers, and consumer advocates on one side, with PBMs and hospital groups on the other, all lobbying furiously as the funding deadline approaches.

The Bottom Line for Consumers and Employers

The financial stakes for American households and businesses are substantial. Analyses of site-neutral payment reforms project significant savings. According to some research, even limited implementation could reduce private health insurance premiums and out-of-pocket costs by over $150 million in a decade. Broader application of the principle could save the healthcare system upwards of $150 billion over ten years, with a direct impact on Medicare, Medicaid, and private insurance premiums.

For individuals, these changes could translate into more predictable medical bills, lower costs at the pharmacy counter, and greater confidence that the doctor they choose is actually in their network. For employers, particularly small and mid-sized businesses, the PBM and site-neutrality reforms offer the prospect of slowing the relentless rise in employee health insurance premiums, freeing up capital for wages and investment.

The continued enforcement of the No Surprises Act remains a critical backstop, ensuring that even when patients navigate the system correctly, they are shielded from financially devastating unexpected bills. The success of these provisions hinges on Congress's ability to navigate the intense lobbying pressure and pass the funding package before the January 30 deadline.